logo-loader
viewProactive Group

Investor Update: Shield Therapeutics targets $1bn US market after FDA approves Feraccru

Top stories from the Proactive Investors UK newsroom.

Shield Therapeutics (LON:STX) has been given approval by the US Food and Drug Administration to sell its lead product Feraccru as a treatment for iron deficiency in adults. The US prescription market for iron replacement therapy is believed to be worth over US$1bn a year.

Motif Bio (LON:MTFB), meanwhile, has been given a date to meet with the FDA to discuss a new clinical study for its antibiotic iclaprim. The in-person meeting has been scheduled for 19 September.

Block Energy (LON:BLOE) has resumed production at the 16aZ well at its flagship West Rustavi field in Georgia.  Production is now running at an average 360 barrels per day

Minds + Machines (LON:MMX) has started its £1mln share buyback programme. The internet registry flagged its intention to buy back shares when it published an upbeat trading statement last week.

Vodafone is to split off its mobile tower business into a separate company that might list. TowerCo comprises 61,700 towers in ten countries and makes underlying profits of €900 million.

Google-owner Alphabet’s second quarter revenue and earnings both beat market expectations, easing concerns about the short-term growth challenges in the face of antitrust investigations.

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Open Orphan PLC's Cathal Friel details merger with 'sleeping giant' hVIVO

Open Orphan PLC's (LON:ORPH) CEO Cathal Friel discusses with Proactive London's Andrew Scott the acquisition of hVIVO PLC (LON:HVO). He says the combination of the businesses will result in synergies across the enlarged group. The firms are complementary to each other with limited overlap...

49 minutes ago

2 min read